AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$IBRX

IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites

ImmunityBio (IBRX) reported a 53% increase in Q3 net product revenue to $48.7M, with 92% growth for the first nine months. The company is testing its drug Anktiva for sepsis and aims to expand FDA approval for bladder cancer. NantWorks, led by Patrick Soon-Shiong, plans a blockchain-based exchange for tokenized securities. IBRX stock has risen 195% over the past year, with bullish retail sentiment on Stocktwits.

Original reporting
finance.yahoo.com
Published Nov 13, 2026, 1:20 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 13, 2026, 1:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
IBRX Stock Eyes Best Year Ever: Founder Teases 12 Months Of ‘Stealth’ NantWorks Reveals — Cancer Tech, AI Chips And Satellites — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$IBRXBullishLow
01

Why it matters

The Q3 earnings beat and new trial initiation provide fresh data points for valuation models.

02

Market read

The article delivers new earnings numbers and trial news that could influence IBRX's short‑term price action.

03

What to watch

Potential regulatory delays or competition in bladder cancer space could temper upside.

Relevance 7/10Novelty 5/10Timing: post-earnings release

Background

ImmunityBio (IBRX) is a biotech focused on immunotherapy for bladder cancer and other indications.

Company-level read

Ticker impact

$IBRXBullishMedium confidence
Context

ImmunityBio reported Q3 net product revenue of $48.7M (up 53% YoY) and announced a Phase 2 sepsis trial, plus progress on the Quilt-2.005 bladder cancer trial.

Expected impact

likely upward pressure as the market prices in strong revenue growth and potential FDA expansion.

Evidence & confidence

Revenue growth and trial updates are fresh disclosures that could attract buying, but no concrete guidance or large contract was announced.

Market effects

Sector

Biotech sector may see modest uplift from ImmunityBio's trial news.

Regional

U.S. biotech investors likely to react positively.

Global

Limited to investors tracking oncology and sepsis therapeutics.

Counterpoint

What could challenge this read

Trial results are early-stage; investors may remain cautious until data readouts.

Key entities

  • company
    ImmunityBio

    Biotech firm reporting earnings and trial updates.

  • clinical_trial
    Sepsis trial

    Phase 2 study of Anktiva in critically ill patients.

Read at source← All news

Related articles

$IBRXHighAI 8/10

IBRX Stock Eyes Worst Week In Nearly 2 Years — But Anktiva’s Sepsis Trial Potential Fuels Retail Bets On Big Pharma Appeal

ImmunityBio (IBRX) saw a 53% year-over-year revenue increase but a 4% sequential decline in Q3. The company plans to seek FDA approval for Anktiva in sepsis treatment by year-end, following positive trial results. Retail sentiment on Stocktwits turned bullish, with investors speculating on potential pharma interest, despite mixed views on immediate stock benefits. IBRX stock is up 237% year-to-date.

finance.yahoo.com
$IBRXHighAI 8/10

What Could ImmunityBio (IBRX) Gain From ANKTIVA Label Expansion And Global Rollout?

ImmunityBio (IBRX) reported positive late-stage data for ANKTIVA in bladder cancer, leading to FDA label expansion in the U.S. and regulatory approval in Israel and Europe. The company aims to widen ANKTIVA's commercial footprint globally. However, ImmunityBio reported a net loss of $184.55 million for Q3 2026, alongside $48.84 million in revenue, highlighting financial risks. Investors are watching ANKTIVA sales trends and global expansion.

finance.yahoo.com
HighAI 8/10

ImmunityBio Stock Sinks 20% as Revenue Misses Estimates Despite Bladder Cancer Trial Win and Israel Approval

ImmunityBio Inc. shares fell 20% after Q3 revenue of $48.84M missed estimates of $59.23M, despite a successful bladder cancer trial and Israel approval. The company reported a loss of 9 cents per share, wider than expected. Revenue grew 53% year-over-year but declined from the prior quarter. Anktiva, its lead product, saw expanded approvals and positive trial results.

ibtimes.com.au